Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
29.9 DKK | +3.10% | -2.61% | +8.93% |
Apr. 23 | Transcript : Embla Medical hf., Q1 2024 Earnings Call, Apr 23, 2024 | |
Apr. 23 | Embla Medical hf. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Summary
- The company has a good ESG score relative to its sector, according to Refinitiv.
Strengths
- Over the past year, analysts have regularly revised upwards their sales forecast for the company.
- The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.
Weaknesses
- The group shows a rather high level of debt in proportion to its EBITDA.
- The company benefits from high valuations in earnings multiples.
- The valuation of the company is particularly high given the cash flows generated by its activity.
- Over the past twelve months, analysts' opinions have been revised negatively.
- The company's earnings releases usually do not meet expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Medical Equipment, Supplies & Distribution
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+8.93% | 1.77B | B+ | ||
-9.29% | 21.39B | B | ||
-6.92% | 16.61B | A | ||
+6.78% | 13.83B | B | ||
+8.45% | 10.5B | B- | ||
-13.54% | 2.16B | - | ||
+42.62% | 1.71B | D- | ||
+13.95% | 584M | - | ||
-.--% | 423M | - | - | |
+29.81% | 132M | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- EMBLA Stock
- Ratings Embla Medical hf.